MINIject’s 2020 results at EGS

The 2020 results from trials of minimally invasive glaucoma surgery (MIGS) device MINIjectTM will be presented at the upcoming European Glaucoma Society (EGS) annual meeting on 12-13 December. The consistently positive data showed outstanding results of intraocular pressure (IOP) and medication reduction in patients with open angle glaucoma, and a positive safety profile across trials.

The final two-year outcomes from the STAR-I clinical trial will be presented by Professor Doctor Philippe Denis, one of the trial investigators and Chair of the Department of Ophthalmology of Croix-Rousse University Hospital of Lyon, France. The one-year data from the European STAR-II trial will be presented by Professor Doctor Katrin Lorenz, Head of the Clinical Study Center at the Eye Clinic, Mainz University Medical Centre, Germany.

“In 2020, the STAR-I and STAR-II results brought very promising news in minimally invasive glaucoma surgery. They consistently confirmed that MINIject is a remarkably effective treatment option for patients, while maintaining very positive safety outcomes,” explained Professor Denis, who was also an investigator in the STAR-II trial. “These data bring promise that soon an optimal, effective and longer-lasting treatment for patients with glaucoma may be possible, while avoiding the risks associated with more invasive eye surgery,” he added.

Both data sets will be presented as on-demand video presentations during the congress and will be available to attendees for three months, and permanently to EGS members. To register: http://www.egs2020.org/node/14